Esmo | Esmo Ovarian cancer is the leading cause of death from gynecological malignancies (Chiang et al., 2013), with a 5-year survival rate of 46% in the United States (92% when localized, 73% with regional metastases, and 28% with distant metastases) (Siegel et al., 2016). (2009). Necessary cookies enable core functionality. Compared to those without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly higher median number of cycles (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test, Table 3). Blood. 2017 Jul 1;28(suppl_4):iv119-iv142. Clinical Practice Guidelines on Supportive Care - ESMO Incidence and Management of Olaratumab Infusion-Related Reactions. View the photographic highlights from ESMO 2017 here! 3, 10 In subsequent trials, 11 - 16 patients were premedicated Copyright 2017 Tai, Tai, Hsu, Lee, Chen, Chiang, Chen, Chen and Cheng. Critical revision: C-AC. sharing sensitive information, make sure youre on a federal 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. Symptoms and signs of hypersensitivity reactions amendable to desensitization. There is a need to further characterise risk of anaphylaxis/hypersensitivity with PH IV/PH FDC SC to support safe administration outside of clinics. Oncol Res Treat. official website and that any information you provide is encrypted This site uses cookies. Multivariate analysis was conducted using logistic regression to estimate the association between the potential risk factors and the occurrence of hypersensitivity. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. The essential content of the guidelinesin condensed slide format in PDF or PowerPoint. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. As shown in Table 6, drug or food history (odd ratios [OR] 2.340, 95% confidence interval [CI] 1.374-3.984, P = 0.0018), malignant ascites (OR 1.895, 95% CI 1.1083.241, P = 0.0196), and cumulative carboplatin dose (4,0004,999 mg: OR 5.507, 95% CI 1.79616.887, P = 0.0028; 5,0009,999 mg: OR 7.244, 95% CI 2.74019.149, P < 0.0001; 10,000 mg: OR 8.461, 95% CI 3.00723.806, P < 0.0001; P for trend < 0.0001) significantly positively correlated with carboplatin hypersensitivity. This was the largest series of gynecological malignancies investigated for carboplatin-related hypersensitivity reactions. Federal government websites often end in .gov or .mil. Educate. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. doi: 10.3322/caac.21332, Sliesoraitis, S., and Chikhale, P. J. 2019 Nov;15(11):e925-e933. 1; Mandac Smoljanovi, Inga 2. Int. All funding for this site is provided directly by ESMO. Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. doi: 10.3802/jgo.2013.24.4.342, Confino-Cohen, R., Fishman, A., Altaras, M., and Goldberg, A. Supportive. Epub 2019 Mar 8. Anticancer. National Library of Medicine Doxorubicin/adriamycin and other chemotherapies present with sudden onset hypo or hypertension in up to 60% of patients and rituximab and other monoclonal antibodies present with cutaneous and cardiovascular symptoms in 70% of the patients. The .gov means its official. Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. We retrieved clinical information, including age, menopausal status, cancer stage, surgical findings, chemotherapeutic treatment history, recurrence status, and survivorship, from the clinical and operative notes and discharge summaries stored in a centralized database. Read guidelines by topic Latest Guidelines News 24, 46994707. The site is secure. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. For more detailed information on the cookies we use, please check our Privacy Policy. Oncol. A sincere thanks to the almost 24,000 participants who attended this year's annual congress! -, A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. ESMO Virtual Congress 2020 | OncologyPRO The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for UK-based media Data to showcase Merck KGaA, Darmstadt, Germany's strong and d. FOIA EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. doi: 10.1093/annonc/mdt333. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . J. Clin. Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH Metrics. sharing sensitive information, make sure youre on a federal (2011). By delivering the target dose of the drug by small incremental doubling doses (Figure 3), the threshold for anaphylaxis is re-established at each step and never reaches that of the initial triggering dose. Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at The cumulative incidence of carboplatin-related hypersensitivity reactions increased with the number of carboplatin cycles (Figure 1A) and increasing dose (Figure 1B), especially at >8 cycles or a dose >3,500 mg. J. Gynecol. Information for media including press accreditation. We also recorded the procedures applied to treat the hypersensitivity reactions and efforts to manage the side effects of carboplatin administration. The MASCC/ESMO guidelines recommend that patients receiving HEC are given a dose of 20 mg dexamethasone on Day 1 to prevent acute emesis; however, if the NK 1 RAs aprepitant or netupitant are also used, a reduced dose of 12 mg dexamethasone is recommended. ESMO 2019 Congress | OncologyPRO J. Swain: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Advisory Role: Exact Sciences (Genomic Health); Financial Interests, Personal, Advisory Role: Molecular Templates; Financial Interests, Personal, Advisory Role: Silverback Therapeutics; Financial Interests, Personal, Advisory Role: Tocagen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Natera; Financial Interests, Personal, Advisory Role: Beijing Medical Foundation; Financial Interests, Personal, Advisory Board: Inivata; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Research Grant: KailosGenetics; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: BMS; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Lilly; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Daiichi-Sankyo; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Caris Life Sciences; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Tan: Non-Financial Interests, Institutional, Research Grant: Genentech/Roche; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Athenex; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. L. Gianni: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: ADC Therapeutics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech, Inc.; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Oncolytics Biotech; Financial Interests, Personal, Advisory Board: Odonate Therapeutics; Financial Interests, Personal, Advisory Board: Onkaido Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Synthon and Zymeworks; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Revolution Medicines; Financial Interests, Personal, Advisory Role: Forty Seven; Financial Interests, Personal, Advisory Role: Metis Precision Medicine; Financial Interests, Personal, Advisory Role: Menarini Ricerche; Financial Interests, Personal, Advisory Role: Synaffix; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Revolution Medicines; Non-Financial Interests, Personal, Other, Patent; EPA 12195182.6 12196177.5-Roche, pending (coinventor): Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Kmmel: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Exact Science; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Daiichi Sanyko; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Somatex; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: PFM medical; Financial Interests, Personal, Advisory Role: Lily; Non-Financial Interests, Personal, Other: Roche; Non-Financial Interests, Personal, Other: Daiichi Sankyo; Non-Financial Interests, Personal, Other: Lily; Non-Financial Interests, Personal, Other: Sonoscape; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Dang: Financial Interests, Personal, Other, Honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Honoraria: Genentech, Inc.; Financial Interests, Personal, Other, Honoraria: Daiichi-Sankyo; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Puma Biotechnology; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Celgene; Financial Interests, Personal, Other, Travel expenses: Roche; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Celgene; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Tesaro; Financial Interests, Personal, Other, Honoraria: Lily; Financial Interests, Personal, Other, Travel expenses: Pfizer; Financial Interests, Personal, Other, Honoraria: Seagen; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. J. O'Shaughnessy: Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Agendia; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Genentech, Inc.; Financial Interests, Personal, Advisory Role: Immunomedics; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Odonate; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Aguila: Financial Interests, Personal, Full or part-time Employment, Clinical Scientist/Medical Director: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Heeson: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd.; Financial Interests, Personal, Stocks/Shares: Roche Products Ltd.; Non-Financial Interests, Personal, Other, Patent; PH FDC SC: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Macharia: Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffman-La Roche. B., Phillips, P. C., Kang, T. I., et al. Please enable it to take advantage of the complete set of features! Cancer. News, highlights and insights download your copy here. All funding for this site is provided directly by ESMO. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. General Information | ESMO 2017 Gynecol. Classical and new chemotherapy drugs, monoclonal antibodies (MoAbs), and small molecules to treat cancer and chronic inflammatory diseases are aimed at improving quality of life and life expectancy of patients, but an increasing number of reactions including anaphylaxis precludes their use in targeted populations. Gynecol. (PDF) Management of cancer pain in adult patients: ESMO Clinical eCollection 2022 Apr. 57, 163167. 2023 Mar 15;210(6):709-720. doi: 10.4049/jimmunol.2100485. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. During the study period, our institution applied carboplatin (including carboplatin with cyclophosphamide or paclitaxel) as the front-line chemotherapy for women with ovarian, fallopian tube, and primary peritoneal cancer. Figure 1. 2014;24(2):72-9; quiz 2 p following 79. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Study conception and design: Y-HT and W-FC. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. The ESMO guideline recommends patients receive surveillance by colonoscopy every 3 years beginning at age 25 for MLH1 and MSH2 mutation carriers and age 35 for MSH6 and PMS2 mutation carriers, or . 103, 608613. (2003) reported that paclitaxel with platinum improves overall survival compared to conventional platinum-based chemotherapy among patients with relapsed platinum-sensitive ovarian cancer. For more detailed information on the cookies we use, please check our Privacy Policy. It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Chan. (1999). Monitor. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. doi: 10.1093/annonc/mdx216. Cancer 63, 2126. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Libra, M., Sorio, R., Buonadonna, A., Berretta, M., Stefanovski, P., Toffoli, G., et al. 57 . Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. 8600 Rockville Pike We invite ESMO members and event attendees to view the 2017 webcasts and presentations using the link below. Abe, A., Ikawa, H., and Ikawa, S. (2010). doi: 10.1093/annonc/mdx225. Cancer 20, 385393. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 107, 163165. Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. Keywords: Efficacy and Adverse Events of Carboplatin Desensitisation Therapy for Gynaecological Cancer: A Retrospective Study. Met Based Drugs (2010) 2010 Available from: Markman M. Toxicities of the platinum antineoplastic agents. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron .